基于超高效液相色谱-质谱法的结肠腺瘤性息肉阳虚体质患者血清代谢物差异研究

Wen-zhang DU; Ai-hua ZHANG; Jun-ling REN; Kun LYU; Lu-yao TUO; Wei XU

doi:10.1007/s11655-019-3181-9

Your Location：

Home >

Browse articles >

基于超高效液相色谱-质谱法的结肠腺瘤性息肉阳虚体质患者血清代谢物差异研究

Original Article | Updated：2022-06-27

- 基于超高效液相色谱-质谱法的结肠腺瘤性息肉阳虚体质患者血清代谢物差异研究
- Study of Differential Serum Metabolites in Patients with Adenomatous Polyps of Colon and Yang-Deficiency Constitution Based on Ultra-Performance Liquid Chromatography-Mass Spectrometry
- Chinese Journal of Integrative Medicine 2022年28卷第5期页码：403-409
- Affiliations：
  
  1.Department of Integrated Traditional Chinese and Western Medicine, First Affiliated Hospital of Harbin Medical University,Harbin (150001), China
  2.Metabolomics Laboratory,Heilongjiang University of Chinese Medicine, Harbin (150001),China
- Author bio：
  
  Prof. XU Wei, E-mail: xuwei_2019@163.com
- Funds：
- DOI：10.1007/s11655-019-3181-9
  中图分类号：
- 纸质出版日期：2022-05-01，
  
  网络出版日期：2019-11-29，
  
  录用日期：2019-08-05
Scan for full text
Wen-zhang DU, Ai-hua ZHANG, Jun-ling REN, 等. 基于超高效液相色谱-质谱法的结肠腺瘤性息肉阳虚体质患者血清代谢物差异研究[J]. Chinese Journal of Integrative Medicine, 2022,28(5):403-409.

Wen-zhang DU, Ai-hua ZHANG, Jun-ling REN, et al. Study of Differential Serum Metabolites in Patients with Adenomatous Polyps of Colon and Yang-Deficiency Constitution Based on Ultra-Performance Liquid Chromatography-Mass Spectrometry[J]. Chinese Journal of Integrative Medicine, 2022,28(5):403-409.
Wen-zhang DU, Ai-hua ZHANG, Jun-ling REN, 等. 基于超高效液相色谱-质谱法的结肠腺瘤性息肉阳虚体质患者血清代谢物差异研究[J]. Chinese Journal of Integrative Medicine, 2022,28(5):403-409. DOI： 10.1007/s11655-019-3181-9.

Wen-zhang DU, Ai-hua ZHANG, Jun-ling REN, et al. Study of Differential Serum Metabolites in Patients with Adenomatous Polyps of Colon and Yang-Deficiency Constitution Based on Ultra-Performance Liquid Chromatography-Mass Spectrometry[J]. Chinese Journal of Integrative Medicine, 2022,28(5):403-409. DOI： 10.1007/s11655-019-3181-9.

摘要

目的:

研究结肠腺瘤性息肉阳虚体质患者与无结肠息肉平衡体质患者血清代谢产物的差异

寻找可用于区分两组的生物标志物.

方法:

收集患者一般资料

收集940例行电子结肠镜检查患者的中医体质. 实验组共纳入结肠腺瘤性息肉、阳虚体质患者119例

对照组纳入无结肠息肉、体质平衡的患者150例. 对两组患者的空腹静脉血进行代谢组学分析. 对检测结果进行主成分分析和正交偏最小二乘判别分析

筛选潜在的生物标志物

确定代谢途径的变化

并讨论所涉及的代谢过程.

结果:

实验组和对照组共鉴定出59个差异生物标志物. 差异代谢物主要存在于甘油磷脂代谢途径中

3-氧代-4-6-二氢胆酸是区分实验组与对照组的生物标志物.

结论:

通过代谢组学分析

可以鉴别出结肠腺瘤性息肉阳虚体质患者与无结肠息肉体平衡体质患者的差异代谢物. 生物标志物3-氧代-4-6-二氢胆酸可能对结肠腺瘤性息肉和阳虚体质患者具有潜在的诊断价值.

Abstract

Objective:

To study the differences between the serum metabolites in patients with adenomatous polyps of the colon and yang-deficiency constitution and those without colon polyps and with balanced constitution

and look for biomarkers that can be used to distinguish between the two groups.

Methods:

General patient information was gathered

and Chinese medicine constitutions were collected in 940 patients who underwent electronic colonoscopy. A total of 119 patients with adenomatous polyps of the colon and yang-deficiency constitution were included in the experimental group

and 150 patients without colon polyps and with balanced constitution were included in the control group. Metabolomics analysis was performed on the fasting venous blood obtained from each patient in both groups. Principal component analysis and orthogonal partial least squares discriminant analysis were performed on the detection results

potential biomarkers were screened

metabolic pathway changes were determined

and the metabolic processes involved were discussed.

Results:

A total of 59 differential biomarkers between the experimental group and the control group were identified. The differential metabolites were found mainly in the glycerophospholipid metabolism pathway

and the bile acid 3-oxo-4

6-choladienoic acid was the biomarker that distinguished the experimental group from the control group.

Conclusions:

With the help of metabolomics analysis

the differential metabolites in patients with adenomatous polyps of the colon and yang-deficiency constitution and those in patients without colon polyps and with balanced constitution could be identified. The biomarker 3-oxo-4

6-choladienoic acid may have potential diagnostic value in patients with adenomatous polyp of the colon and yang-deficiency constitution. (Trial Registration No. NCT02986308)

关键词

Keywords

ultra-performance liquid chromatography-mass spectrometryadenomatous polypsyangdeficiency constitutionChinese medicinemetabolomicsbiomarkers

references

Zhang T, He WT, Zi MJ, Song G, Yi DH, Yang YF. Cohort study on prognosis of patients with metastatic colorectal cancer treated with integrated Chinese and Western medicine. Chin J Integr Med 2018;24:573-578.

Chakradhar S. Colorectal cancer: 5 big questions. Nature 2015;521:S16.

Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014;383:1490-1502.

Zhu Y, Shi H, Wang Q, Wang Y, Yu X, Di J, et al. Association between nine types of tcm constitution and five chronic diseases: a correspondence analysis based on a sample of 2,660 participants. Evid Based Complement Alternat Med 2017;2017:943-968.

Sang XX, Wang ZX, Liu SY, Wang RL. Relationship between traditional Chinese medicine (TCM) constitution and TCM syndrome in the diagnosis and treatment of chronic diseases.Chin Med Sci J 2018;33:114-119.

You H, Zhang T, Feng W, Gai Y. Association of TCM body constitution with insulin resistance and risk of diabetes in impaired glucose regulation patients. BMC Complement Altern Med 2017;17:459-468.

Classification and Judgment of TCM Constitution (ZYYXH/T157-2009). Word J Integr Tradit West Med (Chin) 2009;4:303-304.

He XH, Wu JY Wu ZP. A computer analysis of the accreditation of abdominal mass in the past dynasties. Shanghai J Tradit Chin Med (Chin) 2004;38(11):62-71.

Xue J, Lin YF, Liu Y, Lu YP, Gao WY, Gong Y, et al.The relationship between the occurrence and biological characteristics of colon polyps and TCM syndromes. Chin J Integr Tradit West Med (Chin) 2011;2:8-18.

Deng L, Chang D, Foshaug RR, Eisner R, Tso VK, Wishart DS,et al. Development and validation of a high-throughput mass spectrometry based urine metabolomic test for the detection of colonic adenomatous polyps. Metabolites 2017;7:E32.

Chen C, Deng L, Wei S, Nagana Gowda GA, Gu H, Chiorean EG, et al. Exploring metabolic profile differences between colorectal polyp patients and controls using seemingly unrelated regression. J Proteome Res 2015;14:2492-2499.

Bandu R, Mok HJ, Kim KP. Phospholipids as cancer biomarkers: Mass spectrometry-based analysis. Mass Spectrom Rev 2018;37:107-138.

Ehehalt R, Braun A, Karner M, Füllekrug J, Stremmel W.Phosphatidylcholine as a constituent in the colonic mucosal barrier—physiological and clinical relevance. Biochim Biophys Acta 2010;1801:983-993.

Kritikou E, van Puijvelde GH, van der Heijden T, van Santbrink PJ, Swart M, Schaftenaar FH, et al. Inhibition of lysophosphatidic acid receptors 1 and 3 attenuates atherosclerosis development in LDL-receptor deficient mice. Sci Rep 2016;6:375-385.

Hata E, Sasaki N, Takeda A, Tohya K, Umemoto E, Akahoshi N, et al. Lysophosphatidic acid receptors LPA4 and LPA6 differentially promote lymphocyte transmigration across high endothelial venules in lymph nodes. Int Immunol 2016;28:283-292.

Afroz S, Yagi A, Fujikawa K, Rahman MM, Morito K, Fukuta T, et al. Lysophosphatidic acid in medicinal herbs enhances prostaglandin E2 and protects against indomethacin-induced gastric cell damage in vivo and in vitro. Prostaglandins Other Lipid Mediat 2018;135:36-44.

Zeng R, Li B, Huang J, Zhong M, Li L, Duan C, et al.Lysophosphatidic acid is a biomarker for peritoneal carcinomatosis of gastric cancer and correlates with poor prognosis. Genet Test Mol Biomarkers 2017;21:641-648.

Hwang SH, Lee BH, Choi SH, Kim HJ, Won KJ, Lee HM, et al. Effects of gintonin on the proliferation, migration, and tube formation of human umbilical-vein endothelial cells: involvement of lysophosphatidic-acid receptors and vascular-endothelial-growth-factor signaling. J Ginseng Res 2016;40:325-333.

Velasco M, O'Sullivan C, Sheridan GK. Lysophosphatidic acid receptors (LPARs): potential targets for the treatment of neuropathic pain. Neuropharmacology 2017;113:608-617.

Zeisig R, Koklic T, Wiesner B, Fichtner I, Sentjurc M. Increase influidity in the membrane of MT3 breast cancer cells correlates with enhanced cell adhesion in vitro and increased lung metastasis in NOD/SCID mice. Arch Biochem Biophys 2007;459:98-106.

Lopez DH, Bestard-Escalas J, Garate J. Tissue-selective alteration of ethanolamine plasmalogen metabolism in dedifferentiated colon mucosa. Biochim Biophys Acta Mol Cell Biol Lipids 2018;1863:928-938.

Camp ER, Patterson LD, Kester M, Voelkel-Johnson C.Therapeutic implications of bioactive sphingolipids: a focus on colorectal cancer. Cancer Biol Ther 2017;18:640-650.

García-Barros M, Coant N, Truman JP, Snider AJ, Hannun YA. Sphingolipids in colon cancer. Biochim Biophys Acta 2014;1841:773-782.

Kurek K, Lukaszuk B, Świdnicka-Siergiejko A. Sphingolipid metabolism in colorectal adenomas varies depending on histological architecture of polyps and grade of nuclear dysplasia. Lipids 2015;50:349-358.

Che XH, Chen CL, Ye XL, Weng GB, Guo XZ, Yu WY, et al.Dual inhibition of COX-2/5-LOX blocks colon cancer proliferation,migration and invasion in vitro. Oncol Rep 2016;35:1680-1688.

Traish AM, Kang HP, Saad F, Guay AT. Dehydroepiandrosterone(DHEA)—a precursor steroid or an active hormone in human physiology. J Sex Med 2011;8:2960-2982,quiz 2983.

Panjari M, Davis SR. DHEA therapy for women: effect on sexual function and wellbeing. Hum Reprod Update 2007;13:239-248.

Qian YS, Zhou XO, Zhang Y, Gao PJ, Zhang WZ, Zhu DL.Study on insulin resistance and genetic polymorphisms in essential hypertension patients of two different kinds of TCM constitution. Chin J Integr Med 2007;13:175-179.

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Pathological Change of Chronic Hepatitis B Patients with Different Tongue Coatings by Circular Multi-omics Integrated Analysis

Chemical Composition, Pharmacological Effects and Clinical Applications of Cinobufacini

Immunomodulatory Function of Pien Tze Huang in T Cell-Mediated Anti-tumor Activity against B16-F10, MC38 and Hep1-6 Tumor Models

Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway

TRAIL and Celastrol Combinational Treatment Suppresses Proliferation, Migration, and Invasion of Human Glioblastoma Cells via Targeting Wnt/β-Catenin Signaling Pathway